KZIA 20-F: SEC filing
Kazia Therapeutics Ltd
Filed with the SEC on · accession 0001193125-26-465487
KZIA filed a 20-F (foreign annual report) with the SEC on Nov 17, 2026. The yearly report of a foreign company listed in the US — the foreign version of a 10-K. The stock moved -5.2% by the first close after the filing.
Summary of the filing
Kazia Therapeutics Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2025, disclosing financial statements and details of numerous equity issuances, including ATM sales, warrant exercises, and equity line of credit draws.
Key details
How KZIA stock reacted
Close before
$5.60
Nov 16, 2026
First close after
-5.18%
$5.31
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for KZIA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for KZIA?
Click hereFrequently asked questions
What did KZIA file with the SEC on Nov 17, 2026?
KZIA filed a 20-F (SEC filing). Kazia Therapeutics Ltd filed its annual report on Form 20-F for the fiscal year ended June 30, 2025, disclosing financial statements and details of numerous equity issuances, including ATM sales, warrant exercises, and equity line of credit draws.
How do I read a 20-F?
The yearly report of a foreign company listed in the US — the foreign version of a 10-K. Read the operating review and the risk factors first. Note the currency the numbers are reported in.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 20-F (foreign annual report): The yearly report of a foreign company listed in the US — the foreign version of a 10-K.
How did KZIA stock react to this filing?
KZIA closed at $5.60 before the filing and $5.31 on Nov 17, 2026 (-5.18%).
Other KZIA SEC filings
- SCHEDULE 13G · SEC filingNov 16, 2026
- SCHEDULE 13G/A · SEC filingOct 2, 2026
- 424B3 · SEC filingSep 22, 2026
- 424B3 · SEC filingSep 22, 2026
- 424B3 · SEC filingSep 22, 2026
- 6-K · Fda approvalSep 22, 2026
- 424B3 · SEC filingSep 22, 2026
- 424B3 · SEC filingSep 18, 2026
- 6-K · SEC filingSep 18, 2026
- 6-K · Fda approvalSep 1, 2026
Get alerts when KZIA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days